Results 31 to 40 of about 1,314 (191)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries [PDF]

British Journal of Ophthalmology, 2018
Aims The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study collecting real-world data on the safety and effectiveness of the 0.2 µg/day fluocinolone acetonide (FAc) implant in patients treated according to the ...
U. Chakravarthy, Simon R. J. Taylor, F. Koch, J. P. Castro de Sousa, C. Bailey   +4 more
semanticscholar   +5 more sources

Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center [PDF]

Biomedicines
Macular edema (ME) remains a primary cause of visual deterioration in uveitis. Visual acuity (VA) can often be maintained using corticosteroid depot systems.
Jasmin Abu Arif, Vitus André Knecht, Anne Rübsam, Vanessa Lussac, Zohreh Jami, Dominika Pohlmann, Bert Müller, Uwe Pleyer   +7 more
doaj   +2 more sources

[Not quite an intraocular UFO: An IFO, "Iluvien floating object"].

Journal Français d'Ophtalmologie, 2022
Y. Ghaffour, F. Varenne, V. Soler
semanticscholar   +4 more sources

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom [PDF]

Eye, 2017
AimsTo compare safety outcomes and visual function data acquired in the real-world setting with FAME study results in eyes treated with 0.2 μg/day fluocinolone acetonide (FAc).MethodsFourteen UK clinical sites contributed to pseudoanonymised data ...
C. Bailey, U. Chakravarthy, A. Lotery, G. Menon, J. Talks, Clare Aintree Faruque Calderdale Robert Martin Atul Bush Bailey Kamal Ghanchi Khan Johnston McKibbin Varma , C. Bailey, Aintree Kamal, F. Ghanchi, Calderdale Khan, R. Johnston, M. Mckibbin, A. Varma, Bushra Mustaq, C. Brand, J. Talks, N. Glover   +16 more
semanticscholar   +3 more sources

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) [PDF]

Therapeutic Advances in Ophthalmology, 2019
Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho, Bernardete Pessoa, Angelina Meireles   +2 more
doaj   +3 more sources

Cost advantage of fluocinolone acetonide implant (ILUVIEN®) versus ranibizumab in the treatment of chronic diabetic macular oedema [PDF]

Global & Regional Health Technology Assessment, 2017
A cost analysis model was developed to evaluate the 3-year cost of treating vision impairment associated with chronic diabetic macular oedema (DMO) with either a single fluocinolone acetonide (FAc) implant or with 14 ranibizumab injections in the ...
Fahd Quhill, Annette Beiderbeck
doaj   +2 more sources

Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants. [PDF]

Ophthalmol Ther
Objectives: To determine whether the types and rates of post-surgical complications associated with the Port Delivery System with ranibizumab (PDS) are comparable with those reported for other ocular implants that cross the sclera.
Holekamp NM, Yaqub M, Ranade SV, Cantrell RA, Singh S, Gazzard G.   +5 more
europepmc   +3 more sources

Fluocinolone Implant for Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome: A Case Report

Case Reports in Ophthalmology, 2021
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare and progressive disorder that predominantly affects both the eyes of young female individuals and can threaten visual function.
Lucía Moreno-Castro, Gerardo Pedro García-García, Joseba Artaraz, Alex Fonollosa   +3 more
doaj   +1 more source

Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

Acta Ophthalmologica, Volume 101, Issue 1, Page 22-33, February 2023., 2023
Abstract Purpose To evaluate topical dexamethasone ophthalmic suspension OCS‐01 (Oculis SA, Lausanne, Switzerland) in diabetic macular edema (DME). Methods This was a multicenter, double‐masked, parallel‐group, randomized, Phase 2 study. Patients aged 18–85 years with DME of <3 years duration, ETDRS central subfield thickness ≥ 310 μm by SD‐OCT, and ...
Einar Stefansson, Thorstein Loftsson, Michael Larsen, András Papp, Kai Kaarniranta, Marion R. Munk, Pravin Dugel, Ramin Tadayoni, DX‐211 study group   +8 more
wiley   +1 more source

Diabetic Macular Oedema Guidelines: An Australian Perspective

Journal of Ophthalmology, Volume 2023, Issue 1, 2023., 2023
The number of people living with diabetes is expected to rise to 578 million by 2030 and to 700 million by 2045, exacting a severe socioeconomic burden on healthcare systems around the globe. This is also reflected in the increasing numbers of people with ocular complications of diabetes (namely, diabetic macular oedema (DMO) and diabetic retinopathy ...
Yew Sen Yuen, Jagjit Singh Gilhotra, Michelle Dalton, Jaskirat S. Aujla, Hemal Mehta, Sanj Wickremasinghe, Gurmit Uppal, Jennifer Arnold, Fred Chen, Andrew Chang, Samantha Fraser-Bell, Lyndell Lim, Janika Shah, Ellie Bowditch, Geoffrey K. Broadhead, Paolo Milani   +15 more
wiley   +1 more source